Oxidative stress and neurodegenerative disease

Neurosciences

Volumn 9, Issue 1, 2004, Pages 19-23

  Al Ayadhi, Laila Y ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ASCORBIC ACID; CATALASE; DOPAMINE TRANSPORTER; ESTROGEN; FREE RADICAL; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; MULTIVITAMIN; NITRIC OXIDE SYNTHASE; PLACEBO; PROSTAGLANDIN F2 ALPHA; REACTIVE OXYGEN METABOLITE; SELEGILINE; SUPEROXIDE DISMUTASE; TRANSFERRIN; UBIDECARENONE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIET SUPPLEMENTATION; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; IRON METABOLISM; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; VITAMIN INTAKE;

EID: 1642471671     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Gassen M, Youdim MBH. Free radicals scavengers: chemical concepts and clinical relevance. J Neural Transm Suppl 1999 56: 193-210.
2. Storz G, Imlay JA. Oxidative Stress. Current Opinion In Microbiology 1999; 2: 188-194.
3. Esterbaner H. Aldehydes of lipid peroxidation. In: McBrien DCH, Slater TF editors. Free radicals, and cancer. London (UK): Academic Press; 1980. p. 101-122.
4. Halliwell B, Gutteridge JMC. Oxygen radicals and nervous system. Trends Neurosci 1985; 8: 22-29.
5. Gerlach M, Riederer P, Yondim MBH. Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium and excitotoxic amino acids. Adv Neurol 1996; 69: 177-194.
6. Minotti G, Aust SD. Redox cycling of iron and lipid peroxidation. Lipids 1992; 27: 219-226.
7. Cerruti C, Sheng P, Ladenheim B, Epstein CJ, Gadet JL. Involvement of oxidative and L-arginin-NO pathway in the neurotoxicity of drug abuse in vitro. Clin Exp Pharmacol Physiol 1995; 22: 381-382.
8. Gracy RW, Talent JM, Kong Y, Conrad CC. Reactive oxygen species: The unavoidable environmental insult? Mutat Res 1999; 428: 17-22.
9. Beckman KB, Ames BN. Oxidative decay of DNA. J Biol Chem 1997; 272: 19633-19636.
10. Schmid-Elsaesser R, Zansinger S, Hungerhuber E, Plesnila N, Baethmann A, Reulen HJ. Superior neuroprotective efficacy of a novel antioxidant (U-101033E) with improved Blood-brain barrier permeability in focal cerebral ischemia. Stroke 1997; 28: 2018-2024.
11. Andrus PK, Fleck TJ, Oostveen JA, Hall ED. Neuroprotective effect of the novel brain-penetrating pyrolopyrimidine antioxidant U-101033E and U-1014067F against post-ischemic degeneration of nigrostriatal neurons. J Neurosci Res 1997; 47: 650-654.
12. Delanty N, Dichter MA. Antioxidant therapy in neurologic disease. Arch Neurol 2000; 57: 1265-1270.
13. May JM, Ou ZC, Mendiatta S. Protection and recycling of a tocopherol in human erythrocytes by intracellular ascorbic acid. Arch Biochem Biophys 1998; 349: 281-289.
14. Liu JF, Lee YW. Vitamin C supplementation restores the impaired vitamin E status of guinea pigs fed oxidized frying oil. JNutri 1998; 128: 116-122.
15. Lethem R, Orrell M. Antioxidants and dementia. Lancet 1997; 349: 1189-1190.
16. Catapono Al. Antioxidant effect of flavonoids [Review]. Angiology 1997; 48: 39-44.
17. Schapira AHV. Evidence for mitochondrial dysfunction in Parkinson's disease, a critical appraisal. Mov Disord 1994; 35: 204-210.
18. Jenner P. New insights into the cause of Parkinson's disease. Neurology 1992; 42: 2241-2250.
19. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994; 344: 796-798.
20. Sofic E, Paulus W, Jellinger K, Redener P, Youdim MBH. Selective increase in iron in substantia nigra Zona compacta of Parkinsonian brains. J Neurochem 1991; 56: 978-982.
21. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE et al. Alteration in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting basal ganglia. Brain 1991; 114: 1953-1975.
22. Youdim MB, Harshak N, Yoshieka M, Araki H, Mukai Y, Gott G. Novel substrate and products of amino-oxidase catalysed reaction. Biochem Soc Trans 1991; 19: 224-228.
23. Jellinger K, Kienzl E, Rumplmair G, Riederer P, Stachelberger H, Ben-Shachar D et al. Iron-Melanin complex in substantia nigra of Parkinsonian brain: an x-ray analysis. J Neurochem 1992; 59: 1168-1171.
24. Sofic E, Lang KW, Tellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992; 142: 128-130.
25. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy Agid F et al. Alteration in glutathione levels in Parkinson's disease and other neurodegenerative disease affecting basal ganglia. Ann Neurol 1994; 36: 348-355.
26. Schultz JB, Lindenau J, Seyfried J, Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 2000; 267: 4904-4911.
27. Nicol D, Santiarbandi Sebalos C, Picot I. Direct evidence for glutathione as mediator of apoptosis in neuronal cell. Biomed Pharmcother 1998; 52: 349-355.
28. McCann SM, Licinio J, Wong ML, Yuw H, Karanth S, Rettori V. The nitric oxide hypothesis of aging. Exp Gerontol 1998; 33: 813-816.
29. Du C, Role LW. Differential modulation of nicotinic acetylcholine receptors subtypes and synaptic transmission in chick sympathetic ganglia by PGE(2). J Neurophysiol 2001; 85: 2498-2508.
30. The Parkinson study group. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-183.
31. Olanow CW, Hanser RA, Gauger L. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38: 771-777.
32. Wu RM, Mohana Kumar KP, Murphy DL, Chiueh CC. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (Selegiline) (Review). Ann N Y Acad Sci 1994; 738: 214-221.
33. Palhagen S, Heinoren EH, Hagglund J. For the Swedish Parkinson Study Group. Selegiline delays the onset of disability in de novo Parkinson patients. Neurology 1998; S1: 520-525.
34. Parker Jr WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson disease. Ann Neurol 1989; 26: 719-723.
35. Kisk SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ et al. Brain cytochrome oxidase in Alzheimers disease. J Neurochem 1992; 59: 776-779.
36. Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer disease. J Neurochem 1994; 63: 2179-2184.
37. Connor JR, Menzies SL, Martin SM, Mufson EJ. A histochemical study of iron transferrin and ferritin in Alzheimers disease. J Neurosci Res 1992; 31: 75-83.
38. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ. Regional distribution of iron and iron-regulatory proteins in the brain imaging and Alzheimers disease. Trends Neurosci 1992; 31: 327-335.
39. Changnon P, Betard C, Robitaille Y, Cholette A, Gauvreau D. Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. Neuro Report 1995; 6: 711-715.
40. Mastrogiacom OF, Bergeron C, Kish SJ. Brain-Ketoglutarate dehydrogenase complex activity in Alzheimer's disease. J Neurochem 1993; 61: 2007-2014.
41. Mecocci P, Macgarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994; 63: 747-751.
42. Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B. An assessment of oxidative damage to protein, lipid and DNA in brain from patient with Alzheimer disease. J Neurochem 1997; 68: 2061-2069.
43. Yankner BA, Davies LR, Fisher S, Villa Komaroff L, Oster-Granite ML, Neve RL. Neurotoxicity of fragment of the amyloid precursor associated with Alzheimer diseases. Science 1989; 245: 417-420.
44. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid beta-peptide. Trends Mol Med 2001; 7: 548-554.
45. Maccioni RB, Munoz JP, Barbeito L. The molecular bases of Alzheimer and other neurodegenerative disorders. Arch Med Res 2001; 32: 367-381.
46. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid b protein toxicity. Cell 1994; 77: 817-822.
47. Harris ME, Hensley K, Butterfield A, Leed le RA, Carney JM. Direct evidence of oxidative injury produced by Alzheimer's β -amyloid peptide in cultured hippocampal neurons. Exp Neurol 1995; 131: 193-202.
48. Sano M, Ernesto C, Thomas RG for the members of the Alzheimer's Disease Cooperative study. A controlled trial of Selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336: 1216-1222.
49. Behl C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid b protein toxicity. Biochem Biophys Res Commun 1992; 186: 944-952.
50. Rocca WA, Hofman A, Braynec C, Breteler MM, Clarke M, Copland JR et al. Frequency and distribution of Alzheimer's disease in Europe. A collaborative study of 1980-1990 prevalence Research Group. Ann Neurol 1991; 30: 381-390.
51. Simpkins JW, Singh M, Bishop J. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol Aging 1994; 15 Suppl 2: S195-S197.
52. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem 1994; 269: 13065-13088.
53. Mudd LM, Torres J, Lopez TF, Montague J. Effects of growth factors and estrogen on the development of septal cholinergic neurons from the rat. Brain Res Bull 1998; 45: 137-142.
54. Behl C, Widmann M, Trapp T, Holsboer F. 17-B Estradiol protects from oxidative stress induced cell death in Vitro. Biochem Biophys Res Commun 1995; 216; 473-482.
55. Behl C, Skutella T, Lezoualch F, Post A, Widmann M, Newton CJ et al. Neuroprotection against oxidative stress by estrogen: Structure activity relationship. Mol Pharmcol 1997; 51: 535-541.
56. Dluzen DE. Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. J Neurocytol 2000; 29: 387-399.
57. Smith KJ, Kapoor R, Flets PA. Demyelination: The role of reactive oxygen and nitrogen species. Brain Pathol 1999; 9: 69-92.
58. Le Vine SM. The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med Hypotheses 1992; 39: 271-274.
59. Greco A, Minghetti L, Sette G, Fieschic C, Levi G. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 1999; 53: 1876-1879.
60. Polidoro G, Dillio C, Arduini A, La Rovere G, Fedrici G. Superoxide dismutase, reduced glutathione and thiobarbituric acid-reactive products in erythrocytes of patients with multiple sclerosis. Int J Biochem 1984: 16: 505-509.
61. Shukla VKS, Jenesen GE, Clansen J. Erythrocyte glutathione peroxidase deficiency in multiple sclerosis. Acta Neurol Scand 1977; 56: 542-550.
62. Szeinberg A, Golem R, Ezzer JB, Savona-Pinhas I, Sadeh M, Braham J. Decreased erythrocyte glutathione peroxidase activity in multiple sclerosis. Acta Neurol Scand 1978; 60: 265-271.
63. Syburra C, Passi S. Oxidative stress in patients with multiple sclerosis. Ukr Biochim Zh 1999; 71: 112-115.
64. Sakai T, Inoue A, Koh CS, Ikeda S. A study of free radicals defense and oxidative stress in the sera of patients with neuroimmunological disorders. Arerugi 2001; 49: 12-18.
65. Zeman D, Adam P, Kalistova H, Sobek O, Kelbich P, Andel J et al. Transferrin in patients with multiple sclerosis: a comparison among various subgroups of multiple sclerosis patients. Acta Neurol Scand 2000; 101: 89-94.
66. Zhang SM, Hernan MA, Olek MJ, Spiegelman D, Willett WC, Ascheriol A. Intake of carotenoids, Vitamin C, and Vitamin E and MS risk among two large cohorts of women. Neurology 2001; 57: 75-80.